Availability of Orkambi on the NHS inquiry

Health and Social Care Committee Closed Inquiry
Opened: 30 Nov 2018 Closed: 30 Nov 2018 Parliament page
The Committee’s inquiry concentrated on the provision and pricing of Orkambi, and other drugs developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis. The Committee considered the positions taken in the negotiations between Vertex and NHS England, and NICE’s assessment of the cost-effectiveness of these drugs. Read more
1 Oral session
22 Letters
1 Event
Activity timeline 24 events
24 Oct
2019
Correspondence
24 Oct
2019
Correspondence
30 May
2019
Correspondence
23 May
2019
Correspondence
23 May
2019
Correspondence
13 Mar
2019
Correspondence
7 Mar
2019
Oral evidence
7 Mar
2019
Formal meeting (oral evidence session) · The Wilson Room, Portcullis House
30 Jan
2019
Correspondence
30 Jan
2019
Correspondence
30 Jan
2019
Correspondence
30 Jan
2019
Correspondence
Oral evidence sessions 1 session
7 Mar 2019
View on parliament.uk
Correspondence 22 letters
24 Oct 2019 From committee Letter to the Chair of the Committee from NHS England, regarding cystic fibrosis drugs, 24 October 2019
Parliament page
24 Oct 2019 To committee Letter from Vertex, regarding the availability of Orkambi on the NHS, 24 October 2019
Parliament page
30 May 2019 To committee Letter from NICE regarding update on the progress of negotiations on the availability of Orkambi for NHS patients in England, 30 May 2019
Parliament page
23 May 2019 To committee Letter from NHS England regarding update on the progress of negotiations on the availability of Orkambi for NHS patients in England, 23 May 2019
Parliament page
23 May 2019 To committee Letter from Vertex Pharmaceuticals regarding update on the progress of negotiations on the availability of Orkambi for NHS patients in England, 23 May 2019
Parliament page
13 Mar 2019 From committee Letter to the Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care regarding the availability of Orkambi on the NHS
Parliament page
30 Jan 2019 Documents from Vertex Pharmaceutical (Europe) Ltd, 16 January 2019
Parliament page
30 Jan 2019 To committee Letter from Vertex to NHSE dated, 16 January 2019
Parliament page
30 Jan 2019 To committee Letter from Vertex to NICE dated, 16 January 2019
Parliament page
30 Jan 2019 Document from NHS England, 16 January 2018
Parliament page
30 Jan 2019 Document from NHS England, 16 January 2018
Parliament page
30 Jan 2019 Document from NICE, 15 January 2019
Parliament page
30 Jan 2019 To committee Letter from NICE to Vertex dated, 13 December 2018
Parliament page
20 Dec 2018 Submission from the parents of a young child with Cystic Fibrosis
Parliament page
20 Dec 2018 Submission from European Association of Bioindustries
Parliament page
20 Dec 2018 Submission from UK BioIndustry Association
Parliament page
20 Dec 2018 Documents from Vertex Pharmaceuticals, 30 November 2018
Parliament page
20 Dec 2018 Documents from the National Institute for Health and Care Excellence (NICE), 29 November 2018
Parliament page
20 Dec 2018 Documents from NHS England, 28 November 2018
Parliament page
20 Dec 2018 To committee Letter from the Chair requesting documents from NHS England, the National Institute for Health and Care Excellence (NICE) and Vertex Pharmaceuticals, 7 November 2018
Parliament page
9 Nov 2018 Letters relating to availability of Orkambi for treatment of cystic fibrosis on the NHS, 7 November 2018
Parliament page
25 Jun 2018 Correspondence with the Secretary of State relating to Orkambi and cystic fibrosis
Parliament page